Advertisement
Organisation › Details
Ipsen S.A. (Euronext: IPN; ADR: IPSEY)
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). *
Start | 2007-08-25 existent | |
Group | Ipsen (Group) | |
Industry | pharmaceutical | |
Region | Paris | |
Country | France | |
Street | 42 rue du Docteur Blanche | |
City | 75016 Paris | |
Tel | +33-1-443043-43 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | F: 1,001 to 5,000 (2022-06-27) |
Currency | EUR | |
Annual sales | 1,671,100,000 (revenue, consolidated (2016) 2016-12-31) | |
Profit | 226,600,000 (2016-12-31) | |
Cash | 425,500,000 (2016-12-31) | |
* Document for »About Section«: Ipsen S.A.. (6/27/22). "Press Release: Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology". Paris & Cambridge, MA. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Ipsen (Group)
- [1] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
- [2] Ipsen S.A.. (9/25/20). "Press Release: Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer". Paris....
- [3] Ipsen S.A.. (12/18/19). "Press Release: Ipsen Announces Departure of David Meek as Chief Executive Officer". Paris....
- [4] Ferring Pharmaceuticals S.A.. (12/18/19). "Press Release: FerGene Appoints David Meek Chief Executive Officer". Cambridge, MA....
- [5] Debiopharm International SA. (6/12/19). "Press Release: Debiopharm and Ipsen Extend Their Strategic Decapeptyl (triptorelin) Partnership for another 15 Years". Lausanne & Paris....
- [6] 3B Pharmaceuticals GmbH. (11/20/18). "Press Release: Ipsen and 3BP Announce First Patient Dosed in Phase I/II Study for First-in-class Radionuclide (IPN01087)". Paris....
- [7] Uniqure N.V.. (6/13/18). "Press Release: Uniqure Announces New Appointments to its Board of Directors". Lexington, MA & Amsterdam....
- [8] Corvidia Therapeutics. (3/29/18). "Press Release: Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer". Waltham, MA....
- [9] Ipsen S.A.. (2/13/17). "Press Release: Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top